The ISH Council would like to acknowledge the assistance of the following Corporate Members who are participating in the ISH and therefore helping to promote the advancement of scientific research and knowledge in hypertension and associated cardiovascular diseases.
Current Corporate Member
Boryung Pharmaceutical Company
Boryung Pharmaceutical Company has continually invested heavily in research and development and made efforts to produce high-quality products to contribute what it can to liberate people from debilitating pain and diseases.
Products such as our Gelfos M, Yongkaksan and Kyushin have been much loved by our customers so much that our company has emerged as the most familiar and trusted household brand in Korea.
In many nations around the world, including Korea, the birthrate is declining steadily while the median age of the population is increasing. This has resulted in an increased occurrence of geriatric diseases afflicting an aging population, an issue that needs to be addressed. And as quality of life is becoming increasingly important, interest in health and well being is also rising.
In line with these trends Boryung Pharmaceutical Company has concentrated on developing new drugs and capitalized on advanced manufacturing and marketing techniques to continuously offer medicines that will enhance the quality of life for everyone. To this end Boryung has been intensively engaged in innovative research and development to seek out new solutions to meet our customers’ present and future needs.
Boryung Pharmaceutical Company promises once again that we will constantly prepare for the future, and continue to grow to be a major contributor to the health of humanity throughout the world.
For more information please visit www.boryung.co.kr
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit: daiichisankyo.com.